
Study finds 2 years of lenalidomide maintenance as effective as indefinite treatment for multiple myeloma.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...



